In addition to DLBCL, we also evaluated BCL2, BCLX, BCLW, and MCL1 expression and the effects of single and combination inhibitors in patient samples of indolent lymphomas that can progress to large B-cell lymphoma [48,49], specifically follicular lymphomas that were either low- or high-grade and marginal zone lymphoma. This evidence concerns the gene MCL1 and marginal zone lymphoma.